merged_eli-lilly-zepbound-price.txt
<other>Gathering relevant information from the article to answer each question concisely.</other>

<question_number>1</question_number>
<answer>They offer an FDA-approved safer alternative at a competitive price, undercutting the need for compounded versions</answer>

<question_number>2</question_number>
<answer>By selling Zepbound directly through LillyDirect, bypassing third-party telehealth providers and delivering vials straight to patients</answer>

<question_number>3</question_number>
<answer>They are not FDA-approved and have less oversight, raising safety, quality, and efficacy concerns</answer>

<question_number>4</question_number>
<answer>They can recapture patients who would otherwise use compounded drugs, even if it undercuts their own pen sales</answer>

<question_number>5</question_number>
<answer>The shortage listing allows compounding until supply is deemed sufficient, so leaving the list would help Lilly curb compounding production</answer>

<question_number>6</question_number>
<answer>They are removing intermediaries and selling directly, reflecting a move toward direct-to-consumer models with transparent pricing</answer>

<question_number>7</question_number>
<answer>It could draw older patients to self-pay despite Medicare not covering weight-loss drugs, potentially risking muscle loss</answer>

<question_number>8</question_number>
<answer>It may lead patients to perceive the official vials as safer, potentially shifting demand away from compounded versions</answer>

<question_number>9</question_number>
<answer>Being on the FDAâ€™s shortage list</answer>

<question_number>10</question_number>
<answer>Introducing a lower-priced FDA-approved option to outcompete compounded products</answer>